Machine learning-based approach to guide the choice between baricitinib and tocilizumab in critical COVID-19 pneumonia treatment: a retrospective cohort study.

Front Med (Lausanne) · 2025 · PMC12819291 · PMID 41574379

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In the external test cohort, differences in overall survival between the two low-risk subgroups did not reach statistical significance, likely because of the very small number of TCZ-treated patients ( n = 12).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.